Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc.

218 F. Supp. 2d 1243, 2002 WL 31028799
CourtDistrict Court, S.D. California
DecidedSeptember 11, 2002
DocketCIV. 02CV0046-B (LAB)
StatusPublished
Cited by5 cases

This text of 218 F. Supp. 2d 1243 (Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc., 218 F. Supp. 2d 1243, 2002 WL 31028799 (S.D. Cal. 2002).

Opinion

ORDER DENYING AS MOOT DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT PURSUANT TO 35 U.S.C. § 102(f) FOR NONJOINDER OF CO-INVENTOR, DENYING REQUEST FOR STAY, AND ORDERING PLAINTIFF TO FILE AMENDED COMPLAINT

BREWSTER, Senior District Judge.

I. INTRODUCTION

Before the Court is Defendants’ Motion for Summary Judgment for Non-Joinder *1244 of Co-Inventor pursuant to 35 U.S.C. § 102(f), which came on for hearing before the Court on August 26, 2002. For the reasons below, the Court denies Defendants’ motion and orders Plaintiff to file an amended complaint.

II. BACKGROUND

Nichols Institute Diagnostics, Inc. (“Nichols”) is the sole licensee of U.S. Patent No. 6,030,790 (“the ’790 Patent”). In its complaint, Nichols states a single claim for infringement of the ’790 Patent against Scantibodies Clinical Laboratory, Inc. and Scantibodies Laboratory, Inc. (“Scantibod-ies” or “Defendants”).

The subject matter of the ’790 Patent was also the subject matter of international patent application number WO 96/10041 (“the international application”), which was filed under the Patent Cooperation Treaty (“PCT”). The PCT provides a procedure for filing a patent application on the international level so that subsequent applications in different nations can claim priority based on the filing date for the international application. 4 Donald S. Chisum, Chisum on Patents § 14.02[4]. However, the PCT “does not alter the substantive requirements of patentability” in other countries. Id. Subsequent applications in the United States are referred to as the “national stage” of the international application. 37 C.F.R. § 1.491 (2001).

The ’790 Patent is the national stage of international application number WO 96/10041. As is required by the PCT, the ’790 application covers the same subject matter as its international counterpart. However, whereas the international application designates as inventors four individuals (Drs. Wolf-Georg Forssmann, Knut Adermann, Dieter Hock, and Marcus Magerlein), the ’790 Patent designates only three (Drs. Adermann, Hock, and Magerlein). The parties agree that Dr. Wolf-Georg Forssmann is, in fact, a co-inventor of the subject matter of the ’790 Patent, and that his name was omitted in the inventorship designation.

Defendants filed the instant summary judgment motion on May 16, 2002, contending that the ’790 Patent was invalid under 35 U.S.C. § 102(f) 1 for non-joinder of a co-inventor. While the motion was pending, on July 1, 2002, Pharis Biotec GmbH, assignee of the ’790 Patent, along with the named inventors, Drs. Adermann, Hock, and Magerlein, and the omitted inventor, Dr. Forssmann, applied to the United States Patent and Trademark Office for correction of inventorship pursuant to 35 U.S.C. § 256 2 and 37 C.F.R. *1245 § 1.324(a), 3 seeking to add Dr. Forssmann to the ’790 Patent. 4 They provided the PTO with copies of the complaint in this action, the answer, Seantibodies’ Notice of Motion and Motion for Summary Judgment for Nonjoinder of Co-Inventor, and Seantibodies’ Memorandum of Points and Authorities in Support of Motion for Summary Judgment. (Dec. James T. Carmichael Supp. Pl.’s Opp. Mot. Summ. J., Ex. 1.)

On July 9, 2002, during the parties’ early neutral evaluation conference pursuant to Rule 26(f), Federal Rules of Civil Procedure, Nichols revealed that there was a pending application for a correction certificate. On July 15th and 16th Seantibodies sent the PTO letters objecting to the certificate’s issuance. (Dec. David C. Doyle Supp. Reply Exs. F, G.) Over Seantibodies’ strenuous objections that the PTO lacked authority to issue the correction certificate while the nonjoinder issue was before this Court, the PTO approved the application. The Certificate of Correction adding Dr. Forssmann to the ’790 Patent was published on August 6, 2002. (Dec. Vicki G. Norton Supp. Pl.’s Sur-reply in Opp. Ex. 10.)

III. STANDARD OF LAW

A. Motion for Summary Judgment

Rule 56 of the Federal Rules of Civil Procedure provides that summary judgment is appropriate if the “pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c). When the facts controlling the application of a rule of law are undisputed, the application raises a question of law for the court. Delbon Radiology v. Turlock Diagnostic Ctr., 839 F.Supp. 1388, 1391 (E.D.Cal.1993). Summary judgment is appropriate in such cases. Id. Such purely legal issues appropriate for resolution in a motion for summary judgment include the interpretation of a statute or regulation. Edwards v. Aguillard, 482 U.S. 578, 581-582, 107 S.Ct. 2573, 96 L.Ed.2d 510 (1987).

IV. MOTION FOR SUMMARY JUDGMENT FOR NONJOINDER OF CO-INVENTOR

A. Arguments

In their first summary judgment brief, which was filed before the parties to the patent applied for a Certificate of Correction in the PTO, Seantibodies sought summary judgment pursuant to 35 U.S.C. § 102(f), under which a patent is rendered invalid for omission of a co-inventor, arguing that the ’790 Patent was invalid for failure to designate Dr. Forssmann as a co-inventor. See Pannu v. Iolab Corp., *1246 155 F.3d 1344, 1350 (Fed.Cir.1998). Scantibodies additionally requested that should the Court grant their motion, and should Nichols choose to correct the error under 35 U.S.C. § 256

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
D. Alaska, 2026
M. v. Kovol
D. Alaska, 2025
Illinois Tool Works, Inc. v. MOC Products Co.
856 F. Supp. 2d 1156 (S.D. California, 2012)
Roche Palo Alto LLC v. Ranbaxy Laboratories Ltd.
551 F. Supp. 2d 349 (D. New Jersey, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
218 F. Supp. 2d 1243, 2002 WL 31028799, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nichols-institute-diagnostics-inc-v-scantibodies-clinical-laboratory-casd-2002.